Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

Summary

The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.

Timeline

Start

2021-10-02

Primary completion

2022-03-12

Completion

2023-01-29

Outcome

Outcome not reported

Stopped: “Public vaccination of approved ancestral strain COVID-19 vaccines will be terminated soon. And boosters must be dosed after ancestral vaccination approved in Japan. The study was terminated for ethical reason to prioritize the ancestral vaccination.”

Drugs

Indications